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Edited by Hans-Dieter KlenkAbstract Infectious HIV-1 requires gp160 cleavage by furin at
the REKR511ﬂ motif (site1) into the gp120/gp41 complex,
whereas the KAKR503 (site2) sequence remains uncleaved. We
synthesized 41mer and 51mer peptides, comprising site1 and
site2, to study their conformation and in vitro furin processing.
We found that, while the previously reported 19mer and 13mer
analogues represent excellent in vitro furin substrates, the pres-
ent extended sequences require heparin for optimal processing.
Our data support the hypothesis of a direct binding of heparin
with site1 and site2, allowing selective exposure/accessibility of
the REKR sequence, which is only then optimally cleaved by fur-
in.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Processing1. Introduction
Human immunodeﬁciency virus type-1 (HIV-1) is the etio-
logical agent for the acquired immunodeﬁciency syndrome
(AIDS). The envelope glycoprotein gp160 is processed by host
proteases into the gp120/gp41 heterodimer. This allows the
virus to infect target cells following the cell surface binding
of the trimeric complex gp120/gp41 to the human CD4 recep-
tor [1], and subsequently to the CXCR4/CCR5 co-receptors
[2,3]. This interaction induces conformational change, which
leads to the dissociation of gp120 from gp41, allowing the
N-terminal gp41 fusion peptide to be inserted into the host cell
membrane [4]. Though the structures of a monomeric gp120
core in complex with the CD4 receptor/Fab 17b [5] and that
of a post-fusion form of gp41 were solved [6], little is known
about the entire Env conformation. In fact, individuallyAbbreviations: HIV-1, human immunodeﬁciency virus type 1; GAGs,
glycosaminoglycans; CD, circular dichroism; AIDS, acquired immu-
nodeﬁciency syndrome; RP-HPLC, reverse phase high performance
liquid chromatography; PC, proprotein convertase; BTMD, before
trans membrane domain; MS, mass spectrometry; AMC, 7-amino-4-
methyl-coumarin; MCA, 7-amido-4-methylcoumarin; TFE, triﬂuoro-
ethanol; SDS, sodium dodecyl sulfate; Tris–HCl, Tris-(hydroxymethyl)
aminomethane–HCl; DMSO, dimethyl sulfoxide; HF, hydroﬂuoric
acid; cmk, chloromethylketone; PBS, phosphate buﬀer saline
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doi:10.1016/j.febslet.2007.11.050gp120 does not mimic its precursor conformation, as two
monoclonal antibodies directed against the V3 loop recognized
gp160, but not gp120 [7].
The Env precursor is cleaved by the proprotein convertase
(PC) furin or furin like-proteases at the REKR511ﬂ site1 [8],
resulting in the fusogenic gp120/gp41 complex. Since the
R511T mutation results in uncleaved gp160 and non-infectious
virus, cleavage is essential for viral entry [9]. In vitro investiga-
tions on peptides encompassing the gp120/gp41 junction con-
ﬁrmed that cleavage occurs at Arg511ﬂ [10]. Interestingly,
upstream of the physiological processing site, a second site2
potential furin motif (KAKR503) is ineﬃciently cleaved. The
exact role of site2 is unknown, though mutations of gp160
KAKR503 sequence result in an unprocessed precursor [11].
Conformational diﬀerences between site1 and site2 may ex-
plain the preference of furin for site1 [12].
Even though short gp160 peptides are eﬃciently cleaved
in vitro by furin at Arg511, the full length gp160 was shown
not to be eﬃciently cleaved ex vivo. This suggests that gp160
structure [11,13], post-translational modiﬁcations [14], as well
as cellular and/or extracellular factors, may also inﬂuence the
eﬃcacy and selectivity of the furin mediated cleavage [15].
Viruses, such as Sindbis [16] and coronavirus [17], bind to tar-
get cells via cell-surface glycosaminoglycans (GAGs). Proteo-
glycans were also shown to facilitate HIV-1 binding to and/
or entry into cells lacking the CD4 receptor [18]. Moreover,
enzymatic removal of cell surface heparan sulfate chains dras-
tically impairs HIV-1 infection of CD4+ cells [19]. This eﬀect
likely implicates gp160 and/or gp120 interaction with GAGs
[20–22]. Many authors identiﬁed the binding site for heparin
or its derivatives within the gp120 V3 loop [21]. However, an
increasing body of evidence points to a possible gp160–GAGs
interaction [22].
To investigate the inﬂuence of the sequence surrounding the
REKR511 motif on gp160 processing eﬃciency, we synthesized
various peptides derived from the gp120/gp41 junction (Table
1). Moreover, as a measure of the modulating role of GAGs on
the furin processing, we evaluated the eﬀect of heparin by both
circular dichroism (CD) and HPLC. We found that the gp120/
gp41 junction itself binds heparin, thus enhancing its furin pro-
cessing.2. Materials and methods
2.1. Peptide synthesis
The synthesis of the 14mer and 19mer was reported [10]. The 18mer,
41mer, and 51mer were synthesized on a semi-automatic synthesizer
(Applied Biosystems, Mod. 431A) using a Rink amide MBHA resinblished by Elsevier B.V. All rights reserved.
Table 1
Peptide sequences
5808 A. Pasquato et al. / FEBS Letters 581 (2007) 5807–5813(NovaBiochem, La Jolla, 0.48 mmol/g, 0.25 mmol), Boc chemistry and
HBTU/HOBt activation. Detachment from the solid support and re-
moval of the side chain protecting groups were achieved treating with
HF:anisole:DMSO:2-mercaptopyridine/10:1:1:1 (1 h, 0 C). Crude
products were puriﬁed by reverse phase high performance liquid chro-
matography (RP-HPLC) on a Delta Pak HR C18 column (Waters,
6 lm, 60A˚, 7.8 · 300 mm). Homogeneity grade was evaluated by RP-
HPLC on a Vydac C18 column (Waters, 5 lm, 300 A˚, 4.6 · 250 mm).
Molecular mass was checked by electrospray-time of ﬂight (TOF) mass
spectrometry (MS; Mariner 5120 API-TOF).
2.2. Circular dichroism
CD spectra were recorded on a Jasco CD spectropolarimeter Model
J-710 with a cylindrical fused quartz cell (path length 0.1 cm). The
spectra are reported in units of mean ellipticity (peptide molecular
weight/number of amide bonds), [H]R (deg cm
2 dmol1) or ellipticity,
[H] (deg cm2). The measurements were performed in water, 10 mM
phosphate buﬀer pH 7, 14 mM sodium dodecyl sulfate (SDS) in
10 mM phosphate buﬀer pH 7, triﬂuoroethanol (TFE) 98%, 20 lM
heparin (Sigma, low molecular weight) in 0.15 M NaCl + 25 mM
Tris-(hydroxymethyl) aminomethane–HCl (Tris–HCl) buﬀer pH 7,
and in 0.15 M NaCl + 25 mM Tris–HCl buﬀer pH 7. Peptide concen-
trations, determined by amino acid analysis or UV absorption, varied
from 18 to 43 lM. The spectra were corrected for the solvents, salts
and heparin minor contributions.
2.3. Recombinant hfurin
The media of BSC40 cells infected with either wild type vaccinia
virus (VV:WT, control) or a soluble form of hfurin (VV:hfurin-
BTMD) [8] were collected 18 h post-infection and concentrated (Cen-
triprep YM-30). Activity was measured with the ﬂuorogenic substrate
Pyr-RTKR-MCA.
2.4. Enzymatic assays
Assays were performed in 100 lL at 37 C on 100 lM peptide in
2 mM CaCl2, 25 mM Tris–HCl buﬀer pH 7.0, 1 mM b-mercap-
toethanol, 2 lL furin (2 relative ﬂuorescence units (RFU); where 1
RFU is deﬁned as 1 pmol 7-amino-4-methyl-coumarin (AMC) re-
leased/min/ll enzyme acting on 100 lM of the ﬂuorogenic substrate
Pyr-RTKR-MCA) or as control 2 lL of media from VV:WT culture
supernatant. When speciﬁed, incubation media also contained
2.5 lM, 20 lM or 25 lM heparin. Heparin alone shows no enzymatic
activity (not shown). At various time points, 20 lL samples were
analyzed by RP-HPLC on a Varian C18 column (5 lm, 100 A˚,
4.5 · 250 mm) and digestion products identiﬁed by mass spectrometry
(MS). Percent cleavage was calculated from precursor areas.
2.5. Inhibition assays
Reactions, performed in 100 lL (25 mM Tris–HCl, 1 mM b-mercap-
toethanol and 2 mM CaCl2, pH 7.0) at 37 C, contained 50 lM Pyr-
RTKR-MCA or 100 lM 19mer as substrate, 2 lL of furin and diﬀer-ent concentrations (1–100 lM) of the 18mer as inhibitor or 5 lM dec-
RVKR-cmk [23]. Enzymatic activity with MCA-conjugated peptidyl
substrate was monitored (360 nm excitation, 460 nm emission) with a
Spectra MAX GEMINI EM microplate spectroﬂuorometer (Molecu-
lar Devices), in the presence or absence of either 20 lMor 100 lM hep-
arin. Inhibition assays with the 19mer were monitored by RP-HPLC.
The IC50 were calculated using GraFit Version 4.09 software.3. Results
3.1. Peptides design
Four peptides, 51mer, 41mer, 19mer and 13mer, spanning
the gp160 cleavage sequence, were synthesized (Table 1). The
13mer containing site1, and the 19mer, which includes site1
and site2, were chosen as Ref. [10]. The extended 41mer and
51mer were synthesized to investigate the inﬂuence of the
regions surrounding the physiological cleavage site on furin
processing. It was reported that a cell-permeable 22mer
sequence KIEPLGVAPTKAKRRVVQREKR511, which does
not contain P 0 residues, interferes with gp160 processing [24].
Thus, to test for a possible in vitro inhibitory function we
also synthesized a 18mer peptide (LGVAPTKAKRRVVQ-
REKR511), mimicking the furin-processing product of the
41mer (Table 1).
3.2. Circular dichroism
The spectra in phosphate buﬀer pH 7.0 and water showed a
diagnostic band with a minimum at 198 nm, suggesting that
the 51mer, 41mer and 19mer are unstructured (Fig. 1A–C).
In the presence of SDS, a red shift of the negative band was
observed with a minimum at 201 nm for the 19mer
(Fig. 1A). Interestingly, based on the 220 nm band intensity,
the same micellar solution induced the 41mer and 51mer to as-
sume a 20% and 21% a-helix conformation respectively
(Fig. 1B,C). This indicates a likely SDS interaction that could
be due to the insertion of the hydrophobic C-terminus into mi-
celles and/or could result from the electrostatic binding of the
positively charged site1 and/or site2 to the negatively charged
micellar surface.
TFE induced order in the structure of the 19mer, 41mer, and
51mer (positive band at 190 nm, two negatives at 206 and
220 nm). The a-helix content was 30% in 98% TFE/H2O for
the 19mer, 59% for 41mer and 62% for 51mer (Fig. 1A–C).
Fig. 1. CD spectra of: (A) 19mer, (B) 41mer, and (C) 51mer in (——) water, (- - - - -) Phosphate buﬀer pH 7, (-Æ-Æ-Æ-) 14 mM SDS, and (– – –)
98%TFE/H2O; (D) water (black), 20 lM heparin (dark gray) in H2O and phosphate buﬀer pH 7.2 (light gray).
Fig. 2. CD spectra of: (A) 19mer, (B) 41mer, and (C) 51mer in (black) 0.15 M NaCl and 25 mM Tris–HCl buﬀer pH 7, and (gray, arrow) 20 lM
heparin in 0.15 M NaCl and 25 mM Tris–HCl buﬀer pH 7.
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tions showed a transition of conformers towards a more struc-
tured population, and gp160 cleavage site is positively charged,
further conformational investigations were performed. The
CD proﬁle of 20 lM heparin is similar to that of water
(Fig. 1D) and that of the 19mer does change in the presence
of heparin (Fig. 2A). In contrast, the CD spectra of the
41mer and the 51mer were signiﬁcantly modiﬁed in the pres-ence versus absence of heparin (Fig. 2B,C). Similar results were
obtained with higher heparin concentrations (100 lM).
3.3. Enzymatic assays
The 13mer and 19mer peptides were digested equally well by
furin at site1 (Tables 2 and 3), showing complete processing at
5 h (Fig. 3A,B). In contrast, the 41mer and 51mer peptides
were either barely or unprocessed, respectively, even after
Table 2
Percent cleavage of the 13mer, 19mer, 41mer, and 51mer upon 2 h and overnight incubation in presence or absence of heparin
Time incubation [h] 13mer 19mer 41mer 51mer
Heparin
– + – + – + – +
% Cleavage
0 0 0 0 0
2 53 54 59 52 0 32 0 8
6 100 100 100 100 0 0
Overnight Traces 40 0 60
Table 3
Fragments sequences derived from cleavage at site1 or site2 and their corresponding theoretical and experimental masses
Precursor Fragments sequence Theoretical mass (Da) Experimental mass (Da)
13mer RVVQREKR 1069.65 1070.26
AVGIG 415.24 415.27
18mer LGVAPTKAKR 1069.65 Undetectable
RVVQREKR 1039.65 Undetectable
PTKAKRRVVQREKR 1751.08 1751.16
19mer AVGIG 415.24 415.27
PTKAKR 699.44 Undetectable
RVVQREKRAVGIG 1466.88 Undetectable
LGVAPTKAKRRVVQREKR 2091.29 2091.30
41mer AVGIGALFLGFLGAAGSTMGAAS 2039.06 Undetectable
LGVAPTKAKR 1039.65 Undetectable
RVVQREKRAVGIGALFLGFLGAAGSTMGAAS 3090.69 Undetectable
YKYKVVKIEPLGVAPTKAKRRVVQREKR 3339.01 Undetectable
51mer AVGIGALFLGFLGAAGSTMGAAS 2039.06 Undetectable
YKYKVVKIEPLGVAPTKAKR 2287.38 Undetectable
RVVQREKRAVGIGALFLGFLGAAGSTMGAAS 3090.69 Undetectable
Fig. 3. RP-HPLC proﬁles of: (A) 13mer digestion and (B) 19mer digestion obtained on a Varian C18 column with UV detector (214 nm). Arrows
indicate the fragments.
5810 A. Pasquato et al. / FEBS Letters 581 (2007) 5807–581324 h digestion at pH 7 (Fig. 4A,B; Tables 1–3). Since in vitro
gp160 cleavage was reported to be optimal at pHs 6–7 [25], fur-
ther assays were performed on the 41mer and 51mer at acidic
conditions (pH 6.3, 6.7), again revealing no diﬀerences with re-
spect to the results obtained at pH 7. Furthermore, similar
data were observed in presence of low levels of denaturants
(0.05% TX-100 or SDS) (not shown).We ﬁrst hypothesized that product inhibition could explain
these results. We thus tested the in vitro ability of the 18mer
peptide, representing the furin-derived product of the 41mer
(Table 1), to inhibit the processing of either the ﬂuorogenic
Pyr-RTKR-MCA or the 19mer peptides. While the 18mer pep-
tide eﬀectively reduced the release of free AMC with an esti-
mated IC50 of 1.6 lM (Fig. 5A), it could only partially
Fig. 4. RP-HPLC proﬁles of the digestion of the (A) 41mer and (B) 51mer obtained on a Varian C18 column with UV detector (214 nm). 20 lL of the
enzymatic assay solution was taken (top) immediately after the addition of the substrate and upon overnight incubation (bottom). Arrows indicate
the fragments, (*) being LGVAPTKAKRRVVQREKR for the 41mer and (**) being AVGIGALFLGFLGAAGSTMGAAS.
Fig. 5. Initial rate versus concentration of the 18mer to assess its eﬀect
on the furin cleavage of: (A) Pyr-RTKR-MCA, and (B) 19mer.
A. Pasquato et al. / FEBS Letters 581 (2007) 5807–5813 5811inhibit the 19mer processing with an IC50 > 100 lM (Fig. 5B).
We conclude that product inhibition cannot explain the inabil-
ity of furin to process the 41mer and 51mer peptides.
Because CD investigations showed a likely binding between
heparin and the 41mer or 51mer (Fig. 2B,C), all four gp160-de-
rived analogues were digested overnight in the absence or pres-
ence of 2.5 lM heparin. Under these conditions, the 13mer and
19mer were digested at site1 with similar rates independent of
the presence of heparin. In contrast, while no signiﬁcant pro-
cessing occurred in the absence of heparin, 40% and 60%
processing at the REKRﬂ site of the 41mer (into an 18mer
product with identical retention time on RP-HPLC to the syn-
thetic version) and 51mer peptides, respectively, were observed
in the presence of 2.5 lM heparin (Fig. 6). As control, we con-
ﬁrmed that the 41mer peptide is not cleaved by the recombi-nant VV:WT-infected culture supernatant (Fig. 6, upper
center panel). Furthermore, cleavage was inhibited by adding
a well known PC-inhibitor, dec-RVKR-cmk (Fig. 6, upper
right panel) [23]. At 25 lM heparin we obtained a more exten-
sive processing, but also noticed precipitation of the peptides
(not shown). Finally, in a separate 6 h furin incubation experi-
ment, the processing of the 41mer and 51mer peptides also
showed a similar enhancement eﬀect of heparin (not shown).
In conclusion, these data indicate a likely heparin-peptide
interaction that may better expose site1, and hence allow more
eﬀective furin cleavage.4. Discussion
Five peptides (Table 1) spanning the gp120/gp41 junction
were investigated to better deﬁne the gp160 glycoprotein cleav-
age. The 19mer and its shorter analogue 13mer were processed
by furin at site1 (REKR511), while site2 (KAKR503), which is
included only in the 19mer, was uncleaved (Fig. 3). The lack
of processing at site2 may be rationalized on the basis of struc-
tural motifs. In fact, the 19mer NMR molecular model in TFE
revealed that site2 is embedded in a helical segment, whereas
site1 is in a exposed loop at the C-terminus of the peptide
[12]. In contrast, the 41mer and 51mer, spanning extensive se-
quence of the gp160 cleavage region, were shown to represent
very poor furin substrates. This suggests that the generated
fragments could either act as inhibitors or that the more ex-
tended regions surrounding the physiological cleavage site pre-
vents eﬀective processing.
Since the possibility of product inhibition by the 18mer was
excluded, we turned our attention towards structural restric-
tions and/or the need of other factors to rationalize the non-
cleavability of the 41mer and 51mer peptides. CD analysis
on the 19mer, 41mer and 51mer in aqueous solution revealed
that the three analogues are unstructured, and yet only the
19mer is digested by furin. Thus, some structural constraints
must exist in the 41mer and 51mer, at least around site1.
The same argument may explain the inability of furin to cleave
Fig. 6. Eﬀect of heparin on the processing of the 41mer and 51mer. Upper panel controls: (left) RFU released versus time upon Pyr-RTKR-MCA
cleavage by furin in (black) the absence, or presence of 20 lM (dark gray) or 100 lM (light gray) heparin; (upper central panel): incubation of the
41mer peptide with recombinant vaccinia WT-infected culture supernatant (control); (upper right panel) eﬀect of decanoyl-RVKR-cmk on the
processing of the 41mer by furin. processing. Lower panels: 20 lL of the enzymatic assay solution containing 2.5 lM heparin was taken (top)
immediately after the addition of the substrate and (bottom) after overnight incubation. Arrows indicate the fragments, (*) being
LGVAPTKAKRRVVQREKR for the 41mer peptide or YKYKVVKIEPLGVAPTKAKRRVVQREKR for the 51mer peptide and (**) being
AVGIGALFLGFLGAAGSTMGAAS.
5812 A. Pasquato et al. / FEBS Letters 581 (2007) 5807–5813at site2 in any substrates used. In an attempt to increase the
41mer and 51mer processing, we added some detergents to en-
hance the peptides backbone ﬂexibility without aﬀecting en-
zyme activity. However, neither TX-100 nor SDS had any
eﬀect.
Therefore, we suspected that cellular/extracellular factors
may inﬂuence the cleavability of gp160 by furin. Indeed, sur-
face proteins containing heparin-binding motifs processed by
furin were reported [16,26]. In particular, Sindbis virus attach-
ment to target cells was enhanced in the presence of heparan
sulfate (HS) via the furin recognition motif of the unprocessed
envelope glycoprotein PE2 [16]. Similarly, peptides derived
from the cleavage site of the human respiratory syncytial virus
(RSV) fusion glycoprotein bind heparin and cellular GAGs
[26]. Since the gp120/gp41 does not form stable trimers, while
unprocessed gp160 does, it was hypothesized that gp160 oligo-
mer attachment to the plasma membrane heparin sulfate oc-
curs via its furin cleavage site [27]. Indeed, the
KAKR503RVVQREKR511 sequence exhibits a basic region,
which contains two potential inverted consensus HS-binding
domains. Thus, it was shown that the aﬃnity of gp160 for hep-
arin is about 3-times higher than that observed for gp120,
implying that gp41 and/or hidden motifs in the mature
gp120 may be involved in heparin binding [22].
CD spectra of the 41mer and 51mer suggest these peptides
could interact with heparin (Fig. 2) and undergo structural
reorganization. In fact, in presence of heparin, the proﬁles
change with respect to those of the peptides alone. The nega-tive band at 198 nm, diagnostic for aperiodic structures, is re-
placed by a positive one. In contrast, it is noteworthy that the
shorter 19mer does not change its CD proﬁle in the presence of
heparin. Since the diﬀerence between the 41mer and the 19mer
lies in 22 hydrophobic residues and the interaction between
heparin and polypeptides is supposed to be electrostatic, these
additional residues may support a favorable peptide conforma-
tion that optimally orients the positively charged side chains
towards the negatively charged sulfate moieties. Our results
agree with a probable glycosaminoglycans-gp160 interaction,
as proposed [22,27], and suggest that the residues spanning
the gp120/gp41 junction may contribute in gp160-GAGs bind-
ing.
Moreover, given that heparin induces a change in the 41mer
and 51mer conformation, which could play a key role in the
enzyme-substrate recognition, we analyzed how it may inﬂu-
ence their furin processing. Surprisingly, while up to 100 lM
heparin did not inﬂuence furin activity on Pyr-RTKR-MCA
processing (Fig. 6, left upper panel), the 41mer and 51mer pep-
tides were digested at site1 (Fig. 6). Therefore, we hypothesize
that heparin induces conformational change, optimally expos-
ing the furin-cleavage REKR511 site. This is the ﬁrst time that
heparin is shown to enhance the in vitro cleavage of precursors
by furin.
In conclusion, this study has shown that, in the absence of
heparin, the 41mer and 51mer gp160 derived peptides repre-
sent very poor furin substrates in vitro, in contrast to the short-
er analogues (13mer and 19mer) that are eﬃciently processed.
A. Pasquato et al. / FEBS Letters 581 (2007) 5807–5813 5813Heparin was shown to strongly interact with the 41mer and
51mer peptides, inducing conformational changes, thereby
exposing site1 for cleavage. Since the 41mer and 51mer pep-
tides may not faithfully mimic the conformation around the
cleavage site within the complete gp160 precursor, more anal-
yses are required to assess if heparin is essential in vivo during
gp160 maturation and how GAGs modulate HIV-1 activity.
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